Rigel Pharmaceuticals (RIGL) Enterprise Value (2010 - 2026)
Rigel Pharmaceuticals (RIGL) posted quarterly Enterprise Value of -$146.7 million for Q1 2026, down 90.25% year-over-year from -$1.5 billion in Q1 2025, and up 5.34% quarter-over-quarter from -$155.0 million in Q4 2025.
Rigel Pharmaceuticals (RIGL) Enterprise Value (2010 - 2026) Analysis & Trends
Rigel Pharmaceuticals' Enterprise Value history runs 17 years deep, the most recent figure standing at -$146.7 million for Q1 2026.
- In Q1 2026, Enterprise Value fell 90.25% year-over-year to -$146.7 million; the TTM figure through Mar 2026 stood at -$146.7 million (down 90.25% YoY), while the FY2025 annual figure was -$155.0 million, down 100.4% from the prior year.
- Enterprise Value for Q1 2026 stood at -$146.7 million, up from -$155.0 million in the prior quarter.
- The five-year high for Enterprise Value was -$49.1 million in Q2 2024, with the low at -$155.0 million in Q4 2025.
- The 5-year median for Enterprise Value is -$77.1 million (2025), against an average of -$84.7 million.
- Peak annual rise in Enterprise Value reached 53.42% in 2022, while the deepest fall reached 173.27% in 2022.
- Rigel Pharmaceuticals' Enterprise Value stood at -$58.2 million in 2022, then grew by 2.19% to -$56.9 million in 2023, then tumbled by 35.81% to -$77.3 million in 2024, then slumped by 100.4% to -$155.0 million in 2025, then grew by 5.34% to -$146.7 million in 2026.
- Business Quant data shows RIGL's Enterprise Value at -$146.7 million in Q1 2026, -$155.0 million in Q4 2025, and -$137.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | -5.18 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -3.94 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -8.46 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 2.12 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -3.31 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.16 Bn |
| 10 | Rigel Pharmaceuticals | 795.39 Mn | 700.06 Mn | 70.18 Mn | -95.33 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -95.33 Mn |
| Mar 31, 2026 | -146.68 Mn |
| Dec 31, 2025 | -154.96 Mn |
| Sep 30, 2025 | -137.14 Mn |
| Jun 30, 2025 | -108.38 Mn |
| Mar 31, 2025 | -77.10 Mn |
| Dec 31, 2024 | -77.32 Mn |
| Sep 30, 2024 | -61.11 Mn |
| Jun 30, 2024 | -49.10 Mn |
| Mar 31, 2024 | -49.55 Mn |
| Dec 31, 2023 | -56.93 Mn |
| Sep 30, 2023 | -62.35 Mn |
| Jun 30, 2023 | -64.36 Mn |
| Mar 31, 2023 | -58.66 Mn |
| Dec 31, 2022 | -58.21 Mn |
| Sep 30, 2022 | -81.64 Mn |
| Jun 30, 2022 | -89.17 Mn |
| Mar 31, 2022 | -107.52 Mn |
| Dec 31, 2021 | -124.97 Mn |
| Sep 30, 2021 | -143.15 Mn |